Pharmacodynamic characteristics, safety profile, and interactions of CDK4/6 inhibitors (CDK4/6i) in HR1/HER2– advanced/metastatic breast cancer

Keyphrases

• Metastatic Breast Cancer 100%
• Safety Profile 100%
• Human Epidermal Growth Factor Receptor 2 (HER2) 100%
• Cyclin-dependent Kinase 4 (CDK4) 100%
• Pharmacodynamics 100%
• Molecular Mechanism 33%
• Dosing Regimen 33%
• Daily Clinical Practice 33%
• Targeted Therapy 33%
• Medicinal Products 33%
• European Medicines Agency 33%
• Hormone Receptor-positive 33%
• Human Epidermal Growth Factor Receptor 2-negative 33%
• Abemaciclib 33%
• Endocrine Therapy 33%
• Palbociclib 33%
• Ribociclib 33%
• Pharmacodynamic Difference 33%
• Cyclin-dependent Kinase 4/6 Inhibitors 33%
• Predicted Toxicity 33%
• Overall Similarity 33%
• Efficacy Profile 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Metastatic Breast Cancer 100%
• Pharmacodynamics 100%
• Endocrine Therapy 33%
• Drug Action 33%
• Hormone Receptor 33%
• Abemaciclib 33%
• Epidermal Growth Factor Receptor 2 33%
• Palbociclib 33%
• Gamma Urogastrone 33%
• Ribociclib 33%
• Cyclin Dependent Kinase 4 33%
• Cyclin Dependent Kinase 6 33%